Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Raloxifene (Evista) vs Zoledronate: Raloxifene (Evista) has the stronger overall evidence (5.3 vs 3/10); they're alternatives for bone health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Raloxifene (Evista) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (1)
Outcomes where both Raloxifene (Evista) and Zoledronate have evidence — compare verdict strength side-by-side.
Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the cited MORE and RUTH trials used 60 mg a day, and MORE also tested 120 mg a day: both doses reduced vertebral fracture risk, and the abstract does not compare side effects between them). For off-label male gynecomastia no cited study gives a dose, none covers men or children, and there is no FDA-approved male dose and the male evidence is thin and retrospective.
Any time of day
Raloxifene hydrochloride 60 mg tablets (approved for postmenopausal osteoporosis and breast-cancer risk reduction)
Approved osteoporosis dosing is a single 5 mg intravenous infusion once yearly, given by a clinician (with adequate calcium/vitamin D and hydration). There is no validated longevity regimen; off-label geroprotective use would follow the same infusion under medical supervision.
Any time of day
Once-yearly intravenous infusion (5 mg)
Months to years
Years
Throughout use
Throughout use
~3 years
Years
First few days after infusion
Variable
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
JAMA (1999) · Rct · n=7705
MORE: multicenter, randomized, double-blind, placebo-controlled trial of raloxifene 60 or 120 mg/day in 7,705 postmenopausal women with osteoporosis, followed up to 36 months
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
JAMA (1999) · Rct · n=7705
Pre-specified breast-cancer analysis of the MORE RCT (7,705 postmenopausal women with osteoporosis), followed a median 40 months
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
J Natl Cancer Inst (2004) · Rct · n=5213
CORE: extension of the randomized MORE trial giving 4 additional years of raloxifene 60 mg/day (n=3,510) vs continued placebo (n=1,703)
Zoledronic acid and clinical fractures and mortality after hip fracture.
The New England journal of medicine (2007) · Rct · n=1065
HORIZON Recurrent Fracture Trial: zoledronate vs placebo after hip fracture (n=1065)
Bisphosphonates and lifespan.
Bone (2020) · Review
Review of bisphosphonates and lifespan/aging
Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2014) · Rct
Randomized fracture-prevention trial in a cognitively impaired hip-fracture population
Raloxifene (Evista) has a higher evidence score (5.3/10 vs 3/10) and wins in 2 of 3 categories.
For bone health, Raloxifene (Evista) has a higher relevance score (76 vs 74).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.